Glaxo/Pfizer Consumer Healthcare Joint Venture Spin-off Notes

Project Description

Glaxo/Pfizer Consumer Healthcare Joint Venture Spin-off Notes

December 16, 2020 – Update

• Good Seeking Alpha article arguing that GSK is undervalued.

December 19, 2019 – Update

• On December 19, 2018, GlaxoSmithKline (GSK) and Pfizer (PFE) announced that they would be merging their consumer health businesses into a joint venture. The joint venture is expected to close in the second half of 2019.
• Within three years of closing, the joint venture will be spun off into a separate public company. The joint venture will have sales of $12.7BN. GSK will have a 68% controlling equity stake while PFE will own the remaining 32%.  The combination will bring together a large category of consumer health brands, including GSK’s Sensodyne, Voltaren and Panadol and Pfizer’s Advil, Centrum, and Caltrate.
• The Joint Venture will be the global leader in OTC products with a market share of 7.3% ahead of its nearest competitor at 4.1%.
• Overview of transaction.